Used as a potent carbonic anhydrase inhibitor, this compound shows promise in the treatment of glaucoma by reducing intraocular pressure. It is designed for enhanced selectivity toward carbonic anhydrase isoforms CA IX and CA XII, which are overexpressed in certain hypoxic tumors, making it a candidate for anticancer therapy, particularly in combination with other agents targeting tumor microenvironments. Its sulfonamide and isoxazole moieties contribute to strong enzyme binding and improved pharmacokinetic properties. Additionally, due to its structural features, it serves as a lead compound in the development of diuretics and anti-epileptic agents.